# Helium-3 MRI Imaging Study in COPD

> **NCT02207452** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 11 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DEVICE:** He-3 MRI
- **DRUG:** Salbutamol
- **DRUG:** Ipratropium
- **DEVICE:** MRI

## Key facts

- **NCT ID:** NCT02207452
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-05
- **Primary completion:** 2011-07-04
- **Final completion:** 2011-07-04
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207452, "Helium-3 MRI Imaging Study in COPD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02207452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*